Health Affairs Blog: The Cost Of A Cure: Revisiting Medicare Part D And Hepatitis C Drugs

This blog post revisits an earlier analysis of the drug Sovaldi (sofosbuvir) using new data released by the Centers for Medicare and Medicaid Services, and considers both the ongoing impact of hepatitis C drugs for Medicare Part D and the broader impli…

Web Event: Rx Drugs and the U.S. Health System: A Conversation about Medicare Prescription Drug Costs

On Wednesday, September 7, from noon to 1 p.m. ET, the Kaiser Family Foundation hosted a web conversation to discuss trends in Medicare prescription drug spending, as well as proposals to reduce costs and forecasts of what beneficiaries can expect in c…

Opioid crisis: Insurers bear brunt of cost burden

As the opioid abuse and addiction crisis intensified, private and public insurers took on more of the cost, according to new research from the Centers for Disease Control and Prevention published in Health more

MedPAC wants to push insurers to curtail Part D drug costs

If a federal advisory panel gets its way, health insurers will soon have greater incentives to manage beneficiaries’ prescription drug use and negotiate discounts with pharmaceutical manufacturers, the New York Times reports.


read more

Five Medicare payment recommendations from MedPAC

The Medicare Payment Advisory Commission’s annual report offers five payment recommendations including reforms for two post-acute care providers, a 10 percent cut to drug payments for safety-net hospitals and changes to Medicare Advantage diagnosis coding.


read more

CMS revises policy on docking star ratings of sanctioned Medicare Advantage plans

Federal regulators have revised their policy for automatically reducing star ratings for Medicare Advantage and Part D plans operating under immediate sanctions, a decision that will benefit health plans that have been hit by enforcement more

CMS ramps up enforcement of Part C, Part D Medicare plan violations

A recently released list of financial penalties imposed on Medicare Part C and Part D plan sponsors shows that the government is increasingly coming down hard on health plans that violate federal regulations.

 read more

CMS sanctions Cigna over ‘substantial failures’ in Medicare plans

Federal regulators have banned Cigna from selling new Medicare products because of issues with its Part C and Part D plans that increased enrollees’ out-of-pocket expenses which led to delays or denials in receiving medical services and prescription drugs.


read more

Electronic pharmacy claims data helps prevent med errors

The use of electronic pharmacy claims data showed significant potential to prevent medication errors among patients with complex medication regimens, according to a study published at the Journal of the American Medical Informatics Assoc…

With a laundry list fraud concerns, Part D payments are far from perfect

As one of the youngest government-run health programs, Medicare Part D has been around for less than a decade, meaning it’s just reaching the beginning stages of adolescence. And, like most…

read more

Older posts «

Explore the Archive